Please login to the form below
Xtandi
This page shows the latest Xtandi news and features for those working in and with pharma, biotech and healthcare.
Bayer gets EU nod for prostate cancer drug Nubeqa
Xtandi and Erleada have been fighting for dominance in the HSPC, which means that Nubeqa will have to prove its efficacy if it is to make a dent in this hotly ... In the phase 3 ARCHES trial, Xtandi in combination with ADT reduced the risk of cancer
Latest news
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide).
-
J&J gets EMA nod for wider use of Erleada in prostate cancer
Maintains a regulatory lead over rival Xtandi. Johnson &Johnson has clinched another approval for its prostate cancer drug Erleada in Europe, maintaining a regulatory lead over rival Xtandi from Astellas and ... Erleada can now be used for mCSPC patients
-
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).
-
Pfizer raises forecast following growth of biopharma business
Pfizer CEO Albert Bourla. Pfizer’s prostate cancer therapy Xtandi (enzalutamide) also grew in alliance revenues by 25% to $225m. ... For Pfizer, the potential approval in this indication could help drive Xtandi's growth even further – the drug picked
-
Lynparza scores another positive phase 3 prostate cancer study
Zytiga (abiraterone acetate) or Pfizer’s Xtandi (enzalutamide). ... The drug was compared to Xtandi or Zytiga in the second-line setting, and also focused on patients with HRRm gene mutations.
More from news
Approximately 30 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Analysts believe the drug could achieve peak sales of around $1.7bn, but will face fierce competition from the likes of Pfizer and Astellas’ established Xtandi. ... It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and
-
Deal Watch August 2016
35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.
-
Deal Watch May 2016
The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
-
Deal Watch March 2016
Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.
-
Astellas: Ten years young
Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide). ... There it is currently conducting a series of investigations in breast cancer to assess
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Dendreon appoints new R&D lead
Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
-
Astellas promotes John Demaree
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
-
Astellas makes senior EMEA appointments
Both men are veterans of Astellas. Dew joined the company in 2006 as senior manager business development and has worked on major products such as Xtandi.
-
Astellas poaches new oncology head from Takeda
She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Trials resume for AZ/Oxford University COVID-19 vaccine
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Roche’s Ocrevus boasts positive long-term data in MS
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
